Evaxion Announces Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD (Tradename of Merck & Co., Inc., Rahway, NJ, USA)
Author: Benzinga Newsdesk | February 20, 2024 08:32am
Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique capabilities and know-how.
Posted In: EVAX MRK